Innocare Pharma
Innocare Pharma, a leading biopharmaceutical company headquartered in China (CN), is dedicated to advancing innovative therapies in the oncology and autoimmune disease sectors. Founded in 2015, the company has rapidly established itself as a key player in the industry, focusing on the development of novel treatments that address unmet medical needs. With a robust pipeline of targeted therapies and monoclonal antibodies, Innocare Pharma distinguishes itself through its commitment to research and development, leveraging cutting-edge technology to enhance patient outcomes. The company has achieved significant milestones, including successful clinical trials and strategic partnerships, solidifying its position in the global market. As Innocare Pharma continues to expand its operational reach, it remains focused on delivering high-quality, effective solutions that improve the lives of patients worldwide.
DitchCarbon Score
How does Innocare Pharma's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Research Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Innocare Pharma's score of 26 is higher than 73% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Innocare Pharma's reported carbon emissions
Innocare Pharma, headquartered in China, reported its carbon emissions data for the year 2023, with total emissions amounting to approximately 12,114,590 kg CO2e from Scope 2 and 19,950 kg CO2e from Scope 1. This marks a significant increase in total emissions compared to previous years, where emissions were approximately 9,835,800 kg CO2e in 2022, 9,236,400 kg CO2e in 2021, and 2,476,590 kg CO2e in 2020. The company has not disclosed any specific reduction targets or initiatives under the Science Based Targets initiative (SBTi) or other climate pledges, indicating a lack of formal commitments to reduce emissions at this time. The absence of Scope 3 emissions data suggests that Innocare Pharma may not be fully accounting for all indirect emissions associated with its operations. Overall, Innocare Pharma's emissions profile highlights the need for enhanced climate commitments and strategies to address its carbon footprint effectively.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|
| Scope 1 | - | - | - | 00,000 |
| Scope 2 | 2,476,590 | 0,000,000 | 0,000,000 | 00,000,000 |
| Scope 3 | - | - | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Innocare Pharma is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
